3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
21
Triple Negative Breast Neoplasms
6
Ovarian Neoplasms
6
Pancreatic Neoplasms
4
Neoplasm Metastasis
3
Neoplasms
2
Fallopian Tube Neoplasms
2
Urologic Neoplasms
1
Unilateral Breast Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neoplasm, Residual
1
Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
HER2-negative Metastatic Breast Cancer
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Interventions
Psychiatric Rehabilitation
8
Magnetic Resonance Spectroscopy
7
Gemcitabine
7
Capecitabine
7
pembrolizumab
6
Early Intervention, Educational
6
Drug Therapy
6
Cyclophosphamide
6
Methods
5
Therapeutics
4
Specimen Handling
4
Mental Status and Dementia Tests
4
Docetaxel
4
veliparib
3
selpercatinib
3
sargramostim
3
palbociclib
3
cediranib
3
Trastuzumab
3
Surveys and Questionnaires
3
Standard of Care
3
Radiotherapy
3
Paclitaxel
3
Oxaliplatin
3
Irinotecan
3
Fluorodeoxyglucose F18
3
Counseling
3
Cisplatin
3
Carboplatin
3
Bortezomib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
niraparib
×
Breast
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts